


Cat No. 61-V83

Crizotinib

5 mg

Crizotinib is a potent ATP competitive inhibitor of c-MET and anaplastic lymphoma kinase (ALK). It has been shown to display antitumor efficacy in multiple tumor models and has been shown to inhibit c-MET dependent proliferation, migration and invasion of tumor cells *in vitro*. Crizotinib is selective for c-MET and ALK against over 120 different kinases.

TECHNICAL INFORMATION



Other Names: PF-02341066, PF-1066, PF-2341066

Chemical Formula: C₂₁H₂₂Cl₂FN₅O

CAS Number: 877399-52-5

Molecular Weight: 450.34

Purity: >98%

Appearance: a crystalline solid

Solubility: DMSO

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

PRODUCT USE

Soluble in DMSO at 25 mg/ml. If precipitate is observed, vortex for 5 minutes. For most cells, the maximum tolerance to DMSO is less than 0.5%.

REFERENCES

1. Cui et al. (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 54(18):6342-63.
2. Rodig et al. (2010) Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs. 11 (12):1477-90.
3. Gerber et al. (2010) ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell. 18(6):548-51.